Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-29 01:06:59 - browse：4

Sen. Bob Menendez (D-N.J.) Michael M. Santiago/Getty Images

WASHINGTON — With mounting calls for embattled Sen. Bob Menendez to resign, the pharmaceutical industry could see one of its historical, and increasingly rare, Democratic allies ousted from Congress.

The New Jersey senator is embroiled in another financial scandal after last week’s indictment over hundreds of thousands of dollars he and his wife allegedly accepted to influence military aid. The charges — which Menendez insists he will beat — come roughly seven years after he was accused of pressuring Medicare officials to resolve a dispute in favor of a lavish political donor. That case ended in a hung jury.

But this time around, Capitol lawmakers and New Jersey Democrats including Sen. Cory Booker, a longtime legislation partner, are calling on Menendez to resign. The mounting pressure and looming court battle spell out a hazy future for one of the pharmaceutical industry’s biggest allies in the Democratic Party.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： California’s proposed $25 per hour health care minimum wage

explore

focus

WSS

HHS names first

HCA discloses massive data breach affecting 11 million patients

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

JPM 2024: Verve Therapeutics looks to mainstream genome editing

As JPM 2024 winds down, some health tech firms project optimism

Designating disabled people as health disparity population is crucial

focus

Wikipedia

hotspot

Heart attack and stroke risk calculators need revising

Heart disease and mental health: A look at cardiac psychology

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

At least 13 dead in Texas as scorching temps continue

It's time to get medical device identifiers over the finish line

Affirmative action in medical school literally saved lives

Why ADHD is under

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

hotspot

As JPM 2024 winds down, some health tech firms project optimism

New menopause drug shows promise in relief for hot flashes

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Study: Pain burden is higher in Black NFL players than white ones

Leqembi, other new Alzheimer’s drugs require better biomarkers

Biden launches a new push to limit health care costs

leisure time

explore

focus

focus